Unique ID issued by UMIN | UMIN000015807 |
---|---|
Receipt number | R000018389 |
Scientific Title | Phase I/II Study of TS-1/Oxaliplatin(SOX) for patients with unresectable advanced or recurrent gastric cancer |
Date of disclosure of the study information | 2014/12/01 |
Last modified on | 2024/05/07 09:34:30 |
Phase I/II Study of TS-1/Oxaliplatin(SOX) for patients with unresectable advanced or recurrent gastric cancer
OCD1409 SOX
Phase I/II Study of TS-1/Oxaliplatin(SOX) for patients with unresectable advanced or recurrent gastric cancer
OCD1409 SOX
Japan |
unresectable advanced or recurrent gastric cancer
Gastrointestinal surgery |
Malignancy
NO
To evaluate the efficacy and safety of TS-1/oxaliplatin (SOX) for patients with unresectable advanced or recurrent gastric cancer.
Safety,Efficacy
Confirmatory
Phase I,II
[Phase I part] To determine recommended dose (RD) and maximum tolerated dose (MTD)
[Phase II part] progression-free survival (PFS)
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
SOX
Oxaliplatin/TS-1
20 | years-old | <= |
Not applicable |
Male and Female
1) Histologically proven gastric cancer (Adenocarcinoma)
2) Unresectable advanced/recurrent gastric cancer, HER2 Negative case
3) Aged over 20 years at the time of registration
4) Performance Status(ECOG):0 or 1
5) A measurable lesions in RECIST criteria is unnecessary
6) Previously not treated chemotherapy or radiotherapy for unresectable gastric cancer
7) Able to receive oral treatment
8) Adequate organ function
9) Life expectance estimated>=3 months
10) Written IC
1) History of serious drug hypersensitivity
2) Pregnant, lactating or women of child-bearing potential. Men who want get partner pregnant
3) Active infections 4
4) Serious complications
5) Serious heart disease
6) Peptic ulcers
7) Sensory neuropathy
8) Diarrhea
9) A case with abdominal dropsy and the hydrothorax to need waste fluid by the sustained drainage custody
10) Brain metastasis
11) Other active malignancies (Nondisease period less than 5 years)
12) Continuous steroid treatment
13) Any other cases who are regarded as inadequate for study enrollment by the investigator
14) Administration contraindication of L-OHP , TS-1 , 5-FU
72
1st name | |
Middle name | |
Last name | Kyoichi Ogata |
Gunma University, Graduate School of Medicine
Department of General Surgical Science
3-39-22 Showa-machi Maebashi Gunma 371-8511
027-220-8224
kogata@gunma-u.ac.jp
1st name | |
Middle name | |
Last name | Kyoichi Kaira |
Gunma University Graduate School of Medicine
Department of Oncology Clinical Development
3-39-22 Showa-machi Maebashi Gunma 371-8511
027-220-8222
kkaira1970@yahoo.co.jp
Gunma University Graduate School of Medicine
None
Self funding
NO
2014 | Year | 12 | Month | 01 | Day |
Unpublished
Completed
2014 | Year | 11 | Month | 26 | Day |
2014 | Year | 11 | Month | 13 | Day |
2014 | Year | 11 | Month | 26 | Day |
2018 | Year | 04 | Month | 05 | Day |
2014 | Year | 12 | Month | 01 | Day |
2024 | Year | 05 | Month | 07 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018389